This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Pfizer, Arena Pharma, Merck, Jazz Pharm and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Arena Pharma, Merck, Jazz Pharm and Sanofi
Top Stock Reports for NVIDIA, Philip Morris & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Philip Morris International Inc. (PM) and Sanofi (SNY).
Does PFE, ARNA Deal Signal Robust Pharma M&A Activity in 2022?
by Kinjel Shah
The Pfizer (PFE)-Arena (ARNA) deal raises hopes that M&A activity will pick up significantly in 2022. as big drugmakers are sitting on huge piles of cash.
Sanofi (SNY) Multiple Myeloma Phase III Study Meets Goal
by Zacks Equity Research
Sanofi's (SNY) phase III study on Sarclisa is the first to meet the primary endpoint of MRD negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
Pfizer (PFE) Gets Approval for New Eczema Drug in Europe
by Zacks Equity Research
Pfizer's (PFE) oral JAK inhibitor, Cibinqo, gets approval for treating atopic dermatitis in adults who are candidates for systemic therapy in Europe.
Moderna's (MRNA) Flu Vaccine Data Fails to Impress Investors
by Zacks Equity Research
Moderna's (MRNA) early-stage flu vaccine data seems promising but it fails to meet investors' expectations.
Glaxo (GSK), Medicago COVID-19 Jab Effective Against Variants
by Zacks Equity Research
Glaxo (GSK) and Medicago's plant-based vaccine achieves more than 70% efficacy rate against COVID-19 and its major variants.
Sanofi's (SNY) Filing for Rare Disease Drug Accepted by EMA
by Zacks Equity Research
The EMA accepts Sanofi's (SNY) regulatory submission seeking approval for olipudase alfa, a potential treatment for acid sphingomyelinase deficiency.
Amicus (FOLD) Filings for AT-GAA in Pompe Disease Accepted by EMA
by Zacks Equity Research
The European Medicines Agency accepts Amicus Therapeutics' (FOLD) MAA for AT-GAA, a potential treatment for Pompe disease.
The Zacks Analyst Blog Highlights: Visa, Broadcom, Morgan Stanley, Sanofi and MercadoLibre
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Visa, Broadcom, Morgan Stanley, Sanofi and MercadoLibre
Top Analyst Reports for Visa, Broadcom & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Broadcom Inc. (AVGO), and Morgan Stanley (MS).
Mirati (MRTX) to Begin Clinical Study in MTAP-Deleted Cancers
by Zacks Equity Research
Mirati (MRTX) submits an investigational new drug application to the FDA for MRTX1719 for the treatment of methylthioadenosine phosphoylase-deleted cancers.
4 Reasons Why You Should Add Glaxo (GSK) to Your Portfolio
by Zacks Equity Research
Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2021/2022, which should boost the top line in the long term
Mirati (MRTX) Beats on Q3 Earnings, Begins NDA Adagrasib Filing
by Zacks Equity Research
Mirati's (MRTX) third-quarter earnings beat estimates. It initiates the NDA submission for adagrasib in second-line NSCLC. Shares rise in after-market trading.
Denali (DNLI) Stock Up Despite Wider-Than-Expected Q3 Loss
by Zacks Equity Research
Denali (DNLI) announces wider-than-expected loss per share for third-quarter 2021. Nonetheless, its shares rise following the announcement.
Regeneron (REGN) Q3 Earnings Beat, REGEN-COV Boosts Growth
by Zacks Equity Research
Regeneron (REGN) beats on Q3 earnings while sales record strong year-over-year growth on the solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.
Novo Nordisk's (NVO) Q3 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected results for Q3. Sales are aided by growth in Diabetes and Obesity Care owing to higher GLP-1 revenues.
Will Eylea, Dupixent, REGEN COV Aid Regeneron (REGN) Q3 Earnings?
by Zacks Equity Research
Regeneron's third-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.
Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab
by Kinjel Shah
Several big drugmakers announce third-quarter 2021 earnings. An FDA panel votes in favor of Pfizer's (PFE) COVID-19 vaccine for use in kids 5 to 11 years of age.
Alnylam's (ALNY) Q3 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Alnylam's (ALNY) earnings and sales miss estimates in the third quarter of 2021. The company reiterates its financial guidance for 2021. Stock down.
BioMarin (BMRN) Beats on Q3 Earnings, Ups 2021 Guidance
by Zacks Equity Research
BioMarin's (BMRN) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company raises total revenue guidance and increases adjusted earnings guidance for 2021.
Sanofi (SNY) Q3 Earnings Beat, Sales Miss, 2021 EPS View Up
by Zacks Equity Research
Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It raises earnings growth guidance range for the year.
Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More
by Zacks Equity Research
Earnings and other updates from bigwigs like Bristol Myers (BMY) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.
Q3 Earnings Season Scorecard and Analyst Reports for Disney, Intel & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Intel Corporation (INTC), and Medtronic plc (MDT).
Regeneron (REGN) Dupixent Meets Goal in Prurigo Nodularis Study
by Zacks Equity Research
Regeneron's (REGN) phase III study on Dupixent for treating adults with uncontrolled prurigo nodularis meets its primary and all secondary endpoints.